Somewhat Favorable Press Coverage Somewhat Unlikely to Impact ABIOMED (ABMD) Share Price
Media stories about ABIOMED (NASDAQ:ABMD) have been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ABIOMED earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 45.758389933547 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Mindray Medical International (MR) vs. ABIOMED (ABMD) Financial Review (americanbankingnews.com)
- Stock Exchange: Climbing The Wall Of Worry – Seeking Alpha (seekingalpha.com)
- Abiomed wins PMA for right heart failure device (medicaldevicedaily.com)
- Manchester United, Amphastar Pharmaceuticals, ABIOMED and more – PRE-MARKET (proactiveinvestors.co.uk)
- Abiomed: Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure (finanznachrichten.de)
ABIOMED (NASDAQ ABMD) opened at 163.96 on Monday. ABIOMED has a 52 week low of $95.14 and a 52 week high of $164.60. The stock’s 50 day moving average price is $152.81 and its 200 day moving average price is $138.79. The company has a market capitalization of $7.23 billion, a P/E ratio of 95.88 and a beta of 0.22.
ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.45 EPS for the quarter, topping the consensus estimate of $0.42 by $0.03. The firm had revenue of $132.47 million during the quarter, compared to the consensus estimate of $130.83 million. ABIOMED had a return on equity of 13.03% and a net margin of 16.13%. The company’s quarterly revenue was up 28.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.29 earnings per share. Analysts anticipate that ABIOMED will post $2.24 earnings per share for the current year.
A number of research analysts have weighed in on ABMD shares. Piper Jaffray Companies set a $145.00 price target on ABIOMED in a research note on Tuesday, July 4th. BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a research note on Thursday, August 10th. Jefferies Group LLC restated a “buy” rating and issued a $175.00 price target on shares of ABIOMED in a research note on Tuesday, August 29th. Morgan Stanley restated an “equal weight” rating and issued a $140.00 price target (up from $135.00) on shares of ABIOMED in a research note on Monday, July 10th. Finally, Zacks Investment Research downgraded ABIOMED from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. ABIOMED presently has a consensus rating of “Buy” and a consensus target price of $158.29.
In related news, Director Eric A. Md Rose sold 982 shares of the stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $145.17, for a total transaction of $142,556.94. Following the completion of the sale, the director now directly owns 13,634 shares of the company’s stock, valued at $1,979,247.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO David M. Weber sold 16,500 shares of the stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $147.63, for a total value of $2,435,895.00. Following the sale, the chief operating officer now directly owns 125,122 shares of the company’s stock, valued at $18,471,760.86. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,500 shares of company stock valued at $7,603,342. Company insiders own 7.00% of the company’s stock.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.